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Abstract
Bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, remains a major healthcare burden.
Despite great progresses in perinatal medicine over the past decades, no cure for BPD has been found. The complex
pathophysiology of the disease further hampers the development of effective treatment strategies, but recent
insights into the biology of mesenchymal stem (MSCs) and progenitor cells in lung development and disease have
ignited the hope of preventing or even treating BPD. The promising results of pre-clinical studies have lead to the first
early phase clinical trials. However, these treatments are experimental and much more needs to be learned about the
mechanism of action and manufacturing of MSCs. In this mini review, we briefly summarize the role of resident and
exogenous MSCs in the development and treatment of BPD.
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Introduction
Premature birth and its associated pathologies remain
one of the major causes of morbidity and mortality in
children. Bronchopulmonary dysplasia (BPD) is the most
common complication of birth before the 28th week of
gestation and morphologically characterized by an arrest
of alveolar growth along with a simplified pulmonary vas-
culature [1–3]. The development of the disease is complex
and includes pre- and postnatal factors like preeclamp-
sia, inflammation, malnutrition, and the exposure of the
immature lung to relative hyperoxia andmechanical stress
ex utero [1, 2].
The arrest of postnatal distal lung development is the
hallmark of the so-called new BPD [2]. This suggests a
role of stem or progenitor cells, the building blocks of
*Correspondence: Marius.Moebius@uniklinikum-dresden.de
1Department of Neonatology and Pediatric Critical Care Medicine, Medical
Faculty and University Hospital Carl Gustav Carus, Technische Universität
Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
2DFG Research Center and Cluster of Excellence for Regenerative Therapies
(CRTD), Technische Universität Dresden, Fetscherstrasse 105, 01307 Dresden,
Germany
Full list of author information is available at the end of the article
growth, development, and regeneration, in the pathogene-
sis of BPD. Besides endothelial and certain epithelial stem
cells [4], precursor cells from the mesenchymal lineage—
mesenchymal stem (MSCs)—are thought to be involved in
this process [5].
MSCs are fibroblast-like shaped cells that reside in vir-
tually all mesodermal tissues of the fetal and adult body—
including the bone marrow, adipose tissue, and lung—as
well as in the placenta and the umbilical cord stroma
[5, 6]. Essential features of MSC are
• Their ability to adhere to plain, uncoated plastic
surfaces used in cell culture procedures
• The expression of CD73, CD90, and CD105 on the
cell’s surface
• Absence of CD34, CD45, CD14/CD11b, CD19/
CD79α, and HLA-DR
• The potency to differentiate along adipogenic,
osteogenic, and chondrogenic lineages in vitro
Due to very low levels of expressed HLA class I and II
molecules, MSCs are immune-privileged and do not trig-
ger an immune response once administered to animals
or humans in an allogeneic setting [7, 8]. This led to a
large amount of clinical studies successfully utilizing the
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pro-angiogenic, anti-inflammatory, or tissue-regenerative
potential of MSCs in adults [9].
Moreover, MSCs have been shown to effectively amelio-
rate experimental BPD when administered in a preventive
or therapeutic approach [10]. These observations resulted
in piloting clinical trials, where MSCs from the umbilical
cord blood were administered to infants at risk for BPD
[11]. Larger studies evaluating the clinical feasibility of this
treatment are underway.
Nevertheless, the actions of the endogenous and ther-
apeutically active exogenous MSCs are not well under-
stood. In here, we briefly review the role of MSCs in the
pathogenesis and treatment of BPD.
MSCs orchestrate normal lung development
The lung is a complex organ deriving from the endoder-
mal (→ epithelium) and mesodermal (→ mesenchyme,
endothelium) germ line. It harbors several stem or pro-
genitor cell types from these lineages, each of them with
specific characteristics and (proposed) roles in lung devel-
opment and regeneration [4].
Early normal lung development depends on the airway
branching with subsequent formation of epithelial buds
(pseudoglandular stage), their narrowing (canalicular
stage) and septation into sacs and the alveolar precursors
(saccular stage, primary septa). Subsequent remodeling
and thinning of the mesenchymal compartment results
in a convergence of capillaries and lung epithelium and
triggers septation of the sacs into mature alveoli (alve-
olar stage, secondary septa). This dramatically increases
the alveolar surface of the lung and ensures easy gas
exchange between blood and air. In humans, alveolariza-
tion starts at approx. 32 weeks of gestation and continues
until the fifth year of life [3, 12]. This process is disturbed
in BPD, leading to the increased oxygen demand defining
BPD [2].
The lung’s mesenchyme—consisting of MSCs,
fibroblasts, and their secreted extracellular matrix
(ECM)—crucially drives andmodulates lung development
[2, 3, 12, 13]. Especially alveolar myofibroblasts, along
with the mesenchymal products elastin, fibroblast growth
factors 9 and 10 (Fgf9, Fgf10), Wnt, and platelet-derived
growth factor alpha (Pdgfα) are involved in normal lung
development by enabling both early epithelial budding
and subsequent alveologenesis by formation of secondary
septa [12, 13].
Lung-MSCs (L-MSCs) represent a diverse popula-
tion of organ-resident mesenchymal progenitors [5, 14].
They have been shown to exhibit a highly lung-specific
gene expression pattern and secrete extensive amounts
of proteins contributing to lung development, includ-
ing the abovementioned ones. Moreover, L-MSCs are
thought to give rise to several other lung mesenchymal
cells like myofibroblasts, lipofibroblasts, and normal lung
fibroblasts during early development and organ matura-
tion until adulthood [5].
Functional experiments substantiated the role of L-
MSCs in normal lung development. In contrast to
stem cell antigen-1 (Sca-1)-positive/CD90-negative lung
(myo-)fibroblasts, Sca-1pos./CD90pos. L-MSCs support the
growth of epithelial progenitors like alveolar epithelial
type II cells (AEC-II) and Clara cells in vitro [15]. Lipofi-
broblasts, proposed descendants of L-MSCs, have been
shown to be involved in early surfactant production by
transferring triglycerides (TG) to AEC-II. The epithelial
cell triggers this reaction by secretion of prostaglandin
E2 and parathyroid hormone-related protein (Pthr-p).
AEC-II further metabolize the received TG—additionally
stimulated by lipofibroblast-derived leptin—to surfactant
(reviewed by Collins/Thébaud [5] and El Agha/Bellusci
[15]). Moreover, co-culture of AEC-II and adult lipofi-
broblasts leads to the formation of small alveolar-like
structures (alveolospheres) in vitro, indicating the vital
role of mesenchymal-epithelial crosstalk in postnatal lung
development and regeneration [16]. Lipofibroblasts fur-
ther store and secrete retinolic acids, important mediators
of alveolar septation, and lung development [15].
Striking evidence for the crucial role of lung mesenchy-
mal progenitors in normal lung development was recently
provided by Dr. Krasnow’s group. Utilizing a sophis-
ticated single-cell labeling in the rodent lung, Kumar
et al. described a diversity of stem/progenitor cell pop-
ulations within the mesenchyme. Each MSC popula-
tion exerted distinct lineage and migration boundaries
and contributed to the formation of stalk mesenchyme,
mesothelium, and smooth muscle surrounding the devel-
oping airways or pulmonary vasculature. Moreover, the
group demonstrated that labeled progenitors of airway
smooth muscle cells orchestrated lung morphogenesis by
inducing differentiation of stalk mesenchymal cells into
airway smooth muscle cells during epithelial budding and
branching morphogenesis. Epithelial signaling alone was
unable to induce this essential process [14]. These results
suggest that L-MSCs do not only act as progenitors of
mature mesenchymal cells but also as “control center” of
lung development by coordinating the fate of other cell
types.
Nevertheless, the MSCs’ hierarchy and function within
the mesenchymal compartment of the lung seems to be
very complex. Further research will focus on elucidating
the pathways of L-MSC differentiation and mechanisms
of interaction with epithelial and endothelial lung cells.
Disruptedmesenchymal development and
impaired lungmaturation
As mentioned previously, normal lung development
depends on the well-orchestrated interaction between
mesenchymal, epithelial, and endothelial cells. In BPD,
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this process is disrupted, leading to the characteristic
arrest of alveolar and capillary development [2, 3].
The observation that the presence of lung-specific
MSCs in the tracheal aspirate of premature newborns pre-
dicts the subsequent development of BPD [17] focused
research on the role of these cells in the pathogene-
sis of the disease. The MSCs isolated from infants who
later developed BPD demonstrated substantial alterations
in the pathways controlling the differentiation towards
myofibroblasts—platelet-derived growth factor (PDGF)-
receptor-α, β-catenin, and TGF β1—in vitro [5, 18].
Disruptions in these pathways have been described to
lead to interstitial fibrosis and reduced formation of sec-
ondary septa, consistent with the histopathological pre-
sentation of BPD [18]. However, the relationship between
the MSCs present in the tracheal aspirate and the tissue-
resident L-MSC is not clear and subject of further
research.
As the lung matures in a hypoxic environment in utero,
postnatal (relative) hyperoxia represents a potent stres-
sors to the immature lung and leading cause of BPD [2].
Hyperoxia triggers inflammatory processes in the lung
which results in aberrant mesenchymal signaling, espe-
cially along the Fgf-10 pathway [13]. Moreover, disrupted
mesenchymal PDGF α/PDGFR-α signaling was observed
in neonatal rodent lungs subjected to 75 % O2 [18]. Both
processes led to disrupted alveolar development.
L-MSCs isolated from human fetal lungs demonstrate
profound alterations in their phenotype and secretory
behavior once cultured in normoxic (21 % O2) and
hyperoxic (60 % O2) atmospheres, including rapid dif-
ferentiation into pro-fibrotic myofibroblasts and reduced
production of elastin and certain other ECM compo-
nents [5]. Elastin is a crucial component of the lung-
ECM, which acts as structural protein and driver of—
especially alveolar—lung development. It is known that
quantitative impairment of lung elastin, i.e., in Eln−/−
mice leads to arrested terminal airway formation. More-
over, structural abnormalities and disrupted deposition
patterns of ECM components have been described in
BPD [2, 13].
In summary, it can be hypothesized that oxygen—along
with other deleterious factors damaging the immature
lung—impairs L-MSCs. These cells may not be able to dif-
ferentiate properly, giving raise to aberrant cell types like
stress-induced myofibroblasts [5]. Further differentiation
and loss of the MSCs’ function to coordinate lung growth,
along with disrupted ECM and cytokine production then
leads to the failure of the lung to mature and develop
postnatally. This hypothesis (Fig. 1) is difficult to prove,
given the diversity of L-MSC populations and the result-
ing complicated methods to label and track them [14]. But
the observation that exogenous MSCs prevent and rescue
BPD strongly supports this concept.
Exogenous MSCs prevent and rescue disrupted
lung development
MSCs have been successfully investigated in a vast num-
ber of preclinical and clinical studies; so far, over 1000
patients have safely been treated with these cells for car-
diovascular, neurological, hemato-oncological, or autoin-
flammatory disorders [9]. Different concepts have been
developed to utilize the beneficial effects of MSCs: (I)
the application of whole cells, (II) the administration of
cell-free concentrated tissue culture supernatants (“condi-
tioned medium” or CdM) containing the MSCs’ secreted
factors, or (III) the usage of purified, defined compo-
nents of these supernatants, i.e., exosomes, small vesicles
containing protein, and microRNA.
The regenerative, anti-inflammatory, and pro-angioge-
nic potential of MSCs [6] derived from the bone marrow
(BM-MSCs), umbilical cord blood (UCB-MSCs), or the
Wharton’s jelly (UC-MSCs) predestinate them for a ther-
apeutic use in experimental BPD. Most of these studies
have been performed in a model of rodent hyperoxia-
induced lung injury, which mimics most of the morpho-
logical and functional features of the “new” BPD. This
includes alveolar and capillary simplification, lung fibrosis
with disordered ECM deposition, pulmonary hyperten-
sion with vascular remodeling, and an influx of inflam-
matory cells [19]. Using this model, the group led by
Dr. Thébaud demonstrated that intratracheal administra-
tion (i.t.) of BM-MSCs prevents the offset of all these
pathophysiological changes [20]. Simultaneously, Aslam
et al. described comparable effects in mice treated intra-
venously with either BM-MSCs or their CdM in a pre-
ventive approach [21]. MSCs are also capable of (partially)
rescuing experimental BPD, which was demonstrated uti-
lizing intratracheal administration of UCB-MSCs. Using
these cells in a preventive approach, improvements in
lung architecture, pulmonary hypertension, and exercise
capacity persisted until adulthood (6 months) of the rats.
[22]. Engraftment of MSCs was surprisingly low in all of
these studies, indicating a mainly paracrine action rather
than an integration and differentiation into lung cells.
These promising reports led to several studies investigat-
ing the effects ofMSCs or their CdM from various sources
in experimental BPD. All of them found comparable and
consistent beneficial effects on the lung architecture and
function [10, 23].
The paracrine effects of MSCs are predominant in BPD,
as indicated by the effective usage of cell-free CdM [23].
Blunting of inflammation—a crucial component of BPD
pathogenesis—seems to account for the immediate ben-
eficial effects. Mainly involved cytokines are interleukin-
10 and TNF-stimulated gene/protein 6, which both act
strongly anti-inflammatory [8]. Moreover, MSC-derived
proteins like stanniocalcin-1 seem to prevent damage
to the endogenous (progenitor) cells by increasing their
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Fig. 1 Hypothesis of the MSCs action in BPD. Exogenous MSCs (yellow) interact with the immature lung tissue (upper lung schema diseased
endogenous lung MSCs gray, thick mesenchymal layer forming the primary septa, containing two layers of capillaries (red) distant from the
epithelium) and secrete exosomes and cytokines and transfer mitochondria (left handed site). This protects and rescues lung development, driving
the maturation of the mesenchyme with healthy endogenous MSCs (blue), formation of secondary septa and thinning of the blood-air barrier (lower
lung schema)
resistance to oxidative stress [24, 25]. Secreted growth
factors like hepatocyte growth factor (HGF) and vas-
cular endothelial growth factor (VEGF) then stimulate
lung development. MSCs also produce exosomes, small
membrane-coated vesicles containing lipids, proteins, and
microRNA. Especially, the microRNA can interfere with
the transcription of certain genes, thereby causing the up-
or downregulation of growth factors in lung cells [10].
However, some authors described that treatment with
CdM fails to cause long-term effects comparable to whole
cell therapy [26], whereas short-term effects of CdM are
equal or even superior [21] to an administration of whole
cells (reviewed by Fung et al. [23]). A direct interaction
of the exogenous MSC with the damaged lung seems to
potentiate their therapeutic efficacy in some cases. Sev-
eral hypotheses exist to explain this phenomenon: It is
known that—besides paracrine effects—MSCs are capa-
ble of modulating inflammation by direct cell-cell contact
with leukocytes [10], which may result in a higher anti-
inflammatory potency of whole cell therapy. Secondly,
MSCs are thought to act as part drug and part device
that senses, integrates, and responds to its surround-
ing with exactly the quantity and quality of therapeuti-
cally active substances needed—an eventually “intelligent
and personalized” therapeutic approach [27]. Moreover,
reconstitution of impaired ATPmetabolism by mitochon-
drial transfer from MSCs to lung cells via specific chan-
nels has been described in acute lung injury [28]. This
could occur as well in the treatment of BPD, causing a
persistent therapeutic effect by permanently transplanted
mitochondria.
MSCs in infants—are we there yet?
The promising preclinical results led to a piloting clinical
study utilizing UCB-MSCs in infants. Chang and col-
leagues used 1 × 107 or 2 × 107 MSCs per kg in nine
premature infants born between 24+0 and 26+4 weeks of
gestation. The cells were administered i.t. between the 5th
and 14th day of life without signs of dose-limiting toxicity
or severe adverse effects. As compared to an age-matched
control group, a trend towards a lower BPD severity was
noted [11]. Several phase 1 and phase 2 trials are under-
way (NCT02443961, NCT02381366, NCT01828957).
However, using MSCs in our most vulnerable patient
population might be—despite of the euphoria around
their healing capacities and the great-looking preclinical
reports—a bit ahead of the science. Besides smaller issues
which can be targeted in clinical trials (patient selection,
administration route, dosing, timing of administration),
one major obstacle hampers the initiation of large, con-
trolled trials using MSCs in infants and other patients:
No standardized, high-quality cell product is available to
test in clinical studies. Many laboratories and companies
developed (and patented) methods to isolate and expand
MSCs from various sources [6, 29]. But no quality con-
trol, method of standardization, or method to determine
the therapeutic activity of an MSC-based cell product
exists. This is of particular interest as all production
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procedures (isolation, expansion, passaging, harvesting)
influence the MSC. This causes differentiation and other
cellular impediments affecting the activity of the final
product, regardless if whole cell, CdM, or purified exo-
some preparations are considered [29]. Without quality
control prior to administration, results from studies—
even when conducted with the same cell type—are not
comparable. Large trials are difficult to initiate and their
results difficult to interpret and compare. Intensive trans-
lational research is required to overcome this issue, and
afterwards, clinical studies will determine not only which
therapeutic approach is themost safe, effective, and effica-
cious but also which target population of infants benefits
most fromMSCs.
Conclusions
L-MSCs orchestrate lung cell growth and therefore play
an important role in normal development. Damage to
endogenous MSCs may occur in BPD and contribute to
its pathogenesis. Exogenous MSCs harbor the fascinat-
ing potential to specifically target several mechanisms
involved in BPD development. Their potential to pro-
tect and regenerate lung cells does not only prevent but
also rescues lung injury at least in animal experiments.
Promising preclinical data warrants piloting clinical stud-
ies, but current cell products are imperfect and hamper
the initiation of large, pivotal trials. Every novel tech-
nology is flawed at the beginning, and trials in patients
seem to answer many questions that cannot be addressed
in the laboratory. But it is imperative to due diligence
and treat our most vulnerable patient population with
the best possible cell product in order to obtain the best
possible rather than the fastest results. Further basic and
translational research, especially concerning the better
characterization and quality control of cellular therapeu-
tics is required before carefully designed clinical trials can
be initiated.With this, cellular therapeutics like MSCs can
become the next game changers in neonatal pulmonary
care.
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